Indivior's opioid treatment sales slump prompts second profit warning
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 10 2024
0mins
Should l Buy ?
Source: Reuters
Profit and Revenue Warnings: Indivior issued its second profit and revenue warning in three months, citing lower sales from its opioid addiction treatment Sublocade due to competition from Brixadi, leading to a significant drop in shares by 21.5%.
Revised Financial Outlook: The company has lowered its revenue forecast for the year to between $1.13 billion and $1.17 billion and adjusted its operating profit expectations down to $260 million to $280 million, while also facing challenges related to funding timing within the U.S. Criminal Justice System.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
